Cargando…
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
SIMPLE SUMMARY: Antibody-Drug Conjugates (ADCs) provide effective anti-cancer treatments. ADC development requires the identification of appropriate tumour-associated antigens that can be targeted by the ADC to effectively kill cancer cells while minimising damage to healthy cells, thus limiting sys...
Autores principales: | Esapa, Benjamina, Jiang, Jiexuan, Cheung, Anthony, Chenoweth, Alicia, Thurston, David E., Karagiannis, Sophia N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046624/ https://www.ncbi.nlm.nih.gov/pubmed/36980732 http://dx.doi.org/10.3390/cancers15061845 |
Ejemplares similares
-
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017) -
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020) -
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022) -
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021) -
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)